Review article

Cancer immunotherapy: mechanism of action

Antonio Juretić orcid.org/0000-0002-6379-9708 ; Department of Clinical Oncology, School of Medicine, University of Zagreb, Zagreb, Croatia; Oncology Clinic, University Hospital Center Zagreb, Zagreb, Croatia

Abstract

The prospect of eff ectively treating cancer patients with immunotherapy is now becoming a clinical reality. This is a consequence of clinically relevant and successful results obtained by applying monoclonal antibodies against immune checkpoint inhibitor receptors and chimeric antigen receptor (CAR) T cell therapy to patients with otherwise lethal cancers. Despite this success, only a limited number of cancer types and a subset of cancer patients currently respond to these therapies. Eff orts are now made to increase the number of cancer types and patients that can be treated successfully. This is an overview of the various approaches taken to this end.

Keywords

cancer immunotherapy; immune checkpoint inhibitor; cancer vaccine; chimeric antigen receptor (CAR); adoptive cell therapy

Hrčak ID:

192119

URI

https://hrcak.srce.hr/192119

Publication date:

21.12.2017.

Article data in other languages: croatian

Visits: 2.887 *